Loading
Novelty Nobility is a Korean antibody company. Its cancer drug NN3201 is an antibody-drug conjugate, an antibody that carries a cell-killing drug, aimed at the c-Kit protein found on some stomach wall tumours (GIST), small cell lung cancer and other cancers.
Novelty Nobility Inc. is a clinical-stage antibody company in Pangyo, Seongnam, Gyeonggi-do, Korea, with a location in Cambridge, Massachusetts, and describes oncology as its primary therapeutic area, with programmes also in ophthalmology and immunology. Its PREXISE antibody discovery platforms produced NN3201, a fully human IgG1 antibody-drug conjugate against c-Kit (CD117) carrying an MMAE payload at a drug-to-antibody ratio of 4 through a site-specific cleavable linker, and NN2802, an anti-c-Kit monoclonal antibody for mast cell diseases that has completed a phase 1a study. Its first registered cancer trial, NCT06805825, a phase 1 dose-escalation and expansion study of NN3201 in c-Kit-expressing tumours including gastrointestinal stromal tumours, small cell lung cancer, adenoid cystic carcinoma, uveal melanoma, neuroendocrine tumours and chromophobe and clear cell renal cell carcinoma, was posted on ClinicalTrials.gov in February 2025.
Shares Chromophobe renal cell carcinoma, Renal cell carcinoma.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Renal cell carcinoma.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours.
Shares Chromophobe renal cell carcinoma, Gastrointestinal stromal tumour (GIST), Renal cell carcinoma.
Shares Uveal melanoma, Renal cell carcinoma.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours.
Shares Chromophobe renal cell carcinoma, Neuroendocrine tumours, Renal cell carcinoma.
Shares Chromophobe renal cell carcinoma, Renal cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/